Adaptimmune Therapeutics plc

Equities

ADAP

US00653A1079

Biotechnology & Medical Research

Market Closed - Nasdaq 04:00:00 2024-04-17 pm EDT 5-day change 1st Jan Change
0.987 USD -4.17% Intraday chart for Adaptimmune Therapeutics plc -22.28% +24.46%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
European Equities Traded in the US as American Depositary Receipts Trend Lower in Wednesday Trading MT
European Equities Traded in the US as American Depositary Receipts Lower in Friday Trading MT
Adaptimmune Therapeutics Says Unit Gets Termination Notice for Strategic Collaboration With Genentech MT
European Equities Traded in the US as American Depositary Receipts Trend Lower in Wednesday Trading MT
European Equities Traded in the US as American Depositary Receipts Higher in Friday Trading, Close Out Week Lower MT
European Equities Traded in the US as American Depositary Receipts Fall in Tuesday Trading MT
European Equities Traded in the US as American Depositary Receipts Start Week Modestly Higher MT
European Equities Traded in the US as American Depositary Receipts Rise Slightly in Wednesday Trading MT
European Equities Traded in the US as American Depositary Receipts Kick Off Week Higher in Monday Trading MT
European Equities Traded in the US as American Depositary Receipts Slightly Higher in Friday Trading MT
European Equities Traded in the US as American Depositary Receipts Ease Wednesday MT
European Equities Traded in the US as American Depositary Receipts Trend Lower in Thursday Trading MT
European Equities Traded in the US as American Depositary Receipts Nudge Lower in Wednesday Trading MT
European Equities Traded in the US as American Depositary Receipts Trend Higher in Tuesday Trading MT
ADRs Close Lower, Immuron Ltd. Declines 17.1% DJ
European Equities Traded in the US as American Depositary Receipts Open Week Lower in Monday Trading MT
ADRs Close Higher; Dada Nexus Ltd. Climbs 30% DJ
Transcript : Adaptimmune Therapeutics plc, Q4 2023 Earnings Call, Mar 06, 2024
Adaptimmune Therapeutics plc Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Earnings Flash (ADAP) ADAPTIMMUNE THERAPEUTICS Reports Q4 Revenue $231,000, vs. Street Est of $26M MT
Adaptimmune Therapeutics plc Reports Earnings Results for the Fourth Quarter Ended December 31, 2023 CI
European Equities Traded in the US as American Depositary Receipts Decline Tuesday MT
European Equities Traded in the US as American Depositary Receipts Trend Lower in Thursday Trading MT
Adaptimmune Therapeutics plc Appoints Cintia Piccina as Chief Commercial Officer, Effective March 18, 2024 CI
European Equities Traded in the US as American Depositary Receipts Open Week Flat in Monday Trading MT
Chart Adaptimmune Therapeutics plc
More charts
Adaptimmune Therapeutics PLC is a clinical-stage biopharmaceutical company. The Company is focused on providing cell therapies to people with cancer. It develops T-cell therapies for solid tumors and has reported responses in multiple solid tumor indications. Its platform helps to identify cancer targets, find and develop cell therapy candidates active against those targets and produce therapeutic candidates for administration to patients. Its cell therapy candidates include genetically engineered T-cell receptors (TCRs) and HLA-independent TCRs (HiTs) where surface proteins are targeted independently of the peptide-HLA complex. Its MAGE-A4 cell therapy franchise includes T-cell therapy products targeting solid tumor indications in which the MAGE-A4 antigen is expressed, with responses seen in eight indications (head and neck, esophagogastric junction, non-small cell lung cancer-squamous, synovial sarcoma, melanoma, urothelial, ovarian and myxoid/round cell liposarcoma indications).
Calendar
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
6
Last Close Price
0.987 USD
Average target price
3.6 USD
Spread / Average Target
+264.74%
Consensus
  1. Stock Market
  2. Equities
  3. ADAP Stock
  4. News Adaptimmune Therapeutics plc
  5. SVB Leerink Adjusts Adaptimmune Therapeutics' Price Target to $3 from $7, Keeps Market Perform Rating